Name:	O
___	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
F	O
Service:	O
MEDICINE	O
Allergies:	O
Cefepime	O
/	O
Meropenem	O
/	O
Ciprofloxacin	O
/	O
Levofloxacin	O
Attending:	O
___.	O
Chief	O
Complaint:	O
fatigue	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
None	O
History	O
of	O
Present	O
Illness:	O
___	O
is	O
a	O
___	O
female	O
with	O
relapsed	O
AML	O
on	O
day	O
15	O
of	O
azacitidine,	O
seen	O
in	O
clinic	O
today	O
for	O
a	O
count	O
check	O
and	O
c/o	O
generalized	O
weakness,	O
fatigue.	O
Denies	O
diarrhea,	O
dysuria/frequency/urgency,	O
cough/SOB.	O
Also	O
w/	O
poor	O
PO	O
intake	O
___	O
nausea	O
(no	O
vomiting).	O
Last	O
BM	O
was	O
3	O
days	O
ago.	O
She	O
denies	O
fevers/chills	O
at	O
home,	O
but	O
was	O
found	O
to	O
be	O
febrile	O
at	O
100.9	O
in	O
clinic	O
today.	O
Also	O
of	O
note,	O
patient	O
seen	O
in	O
ED	O
on	O
___	O
with	O
nausea/weakness,	O
found	O
to	O
have	O
platelets	O
of	O
10,000	O
w/	O
numerous	O
ecchymoses/etechiae	O
on	O
chest	O
and	O
transfused	O
platelets.	O
.	O
She	O
was	O
recently	O
admitted	O
for	O
cellulitis	O
around	O
her	O
mouth	O
and	O
is	O
on	O
clindamycin	O
for	O
this.	O
States	O
she	O
missed	O
her	O
doses	O
of	O
clindamycin	O
on	O
___	O
because	O
she	O
was	O
in	O
the	O
ED,	O
but	O
other	O
than	O
that	O
has	O
been	O
able	O
to	O
take	O
all	O
pills	O
despite	O
nausea.	O
Denies	O
dysphagia.	O
States	O
she	O
has	O
been	O
taking	O
her	O
voriconazole.	O
Her	O
blast	O
count	O
has	O
continued	O
to	O
rise	O
despite	O
a	O
recent	O
course	O
of	O
azacitidine.	O
.	O
She	O
is	O
admitted	O
for	O
management	O
of	O
her	O
fevers,	O
anemia,	O
and	O
thrombocytopenia.	O
Past	O
Medical	O
History:	O
Ms.	O
___	O
was	O
diagnosed	O
with	O
AML	O
in	O
___.	O
She	O
had	O
7+3	O
treatment	O
complicated	O
by	O
febrile	O
neutropenia	O
and	O
pneumonia.	B-Lower_respiratory_tract_infection
She	O
has	O
undergone	O
low-dose	O
chemotherapy	O
(cytarabine/idarubicin)	O
as	O
an	O
outpatient.	O
She	O
received	O
4	O
cycles	O
of	O
ALFA-low	O
dos	O
cytarabine/idarubicin.	O
Her	O
counts	O
were	O
slow	O
to	O
recover	O
and	O
there	O
was	O
concern	O
over	O
MDS.	O
___	O
to	O
neupogen	O
injections.	O
She	O
underwent	O
a	O
bone	O
marrow	O
biopsy	O
in	O
___	O
which	O
showed	O
52%	O
blasts.	O
She	O
had	O
no	O
circulating	O
blasts	O
at	O
that	O
time.	O
She	O
received	O
her	O
first	O
cycle	O
of	O
decitibine	O
___	O
to	O
___.	O
She	O
tolerated	O
treatment	O
well	O
per	O
report.	O
On	O
___	O
she	O
had	O
4%	O
circulating	O
blasts.	O
This	O
increased	O
to	O
63%.	O
Now	O
Day	O
___	O
s/p	O
azacitidine.	O
.	O
PAST	O
MEDICAL	O
HISTORY:	O
-	O
AML	O
-	O
Glaucoma	B-Visual_impairment
with	O
bilateral	O
cataract	O
surgery	O
in	O
___	O
and	O
___	O
-	O
Lung	O
lesions	O
during	O
induction	O
suspicious	O
for	O
Aspergillus.	O
Social	O
History:	O
___	O
Family	O
History:	O
Mother	O
-	O
deceased	O
at	O
age	O
___	O
from	O
Alzheimer's	B-Dementia
Disease.	O
Father	O
-	O
deceased	O
at	O
age	O
___.	O
She	O
has	O
a	O
brother	O
who	O
is	O
healthy.	O
.	O
Physical	O
Exam:	O
VS:	O
97.5,	O
115/60,	O
82,	O
20,	O
98RA	O
GENERAL:	O
fatigued,	O
pleasant,	O
alert	O
and	O
oriented	B-Delirium
x3	B-Delirium
HEENT:	O
EOMI,	O
PERRLA,	O
oropharynx	O
dry,	O
+thrush	O
NODES:	O
No	O
cervical,	O
supraclavicular	O
LAD	O
LUNGS:	O
Clear	O
to	O
auscultation	O
bilaterally.	O
HEART:	O
RRR,	O
___	O
SEM	O
ABDOMEN:	O
Soft,	O
nontender,	O
nondistended,	O
with	O
no	O
palpable	O
masses	O
or	O
hepatosplenomegaly.	O
EXT:	O
No	O
clubbing,	O
cyanosis,	O
or	O
edema	O
SKIN:	O
Resolving	O
drug	O
rash	O
over	O
both	O
legs,	O
2	O
flesh	O
colored	O
papules	O
over	O
left	O
forearm	O
surface	O
Pertinent	O
Results:	O
Labs	O
on	O
admission:	O
___	O
08:20AM	O
GLUCOSE-136*	O
UREA	O
N-13	O
CREAT-0.5	O
SODIUM-134	O
POTASSIUM-3.5	O
CHLORIDE-94*	O
TOTAL	O
CO2-27	O
ANION	O
GAP-17	O
___	O
08:20AM	O
WBC-1.1*	O
RBC-2.75*	O
HGB-8.8*	O
HCT-25.6*	O
MCV-93	O
MCH-32.0	O
MCHC-34.3	O
RDW-16.6*	O
___	O
08:20AM	O
NEUTS-4*	O
BANDS-0	O
LYMPHS-51*	O
MONOS-4	O
EOS-0	O
BASOS-0	O
ATYPS-8*	O
___	O
MYELOS-0	O
BLASTS-33*	O
OTHER-0	O
___	O
08:20AM	O
PLT	O
SMR-RARE	O
PLT	O
COUNT-10*#	O
___	O
08:20AM	O
___	O
PTT-35.1*	O
___	O
___	O
10:00AM	O
ALT(SGPT)-15	O
AST(SGOT)-19	O
LD(LDH)-194	O
ALK	O
PHOS-68	O
TOT	O
BILI-0.5	O
Labs	O
on	O
discharge:	O
___	O
12:00AM	O
BLOOD	O
WBC-0.7*	O
RBC-2.87*	O
Hgb-8.8*	O
Hct-26.5*	O
MCV-92	O
MCH-30.6	O
MCHC-33.1	O
RDW-13.7	O
Plt	O
Ct-18*	O
___	O
12:00AM	O
BLOOD	O
Neuts-0	O
Bands-0	O
Lymphs-98*	O
Monos-0	O
Eos-0	O
Baso-0	O
___	O
Myelos-0	O
Blasts-2*	O
___	O
12:00AM	O
BLOOD	O
Glucose-118*	O
UreaN-11	O
Creat-0.5	O
Na-141	O
K-3.8	O
Cl-103	O
HCO3-30	O
AnGap-12	O
___	O
12:00AM	O
BLOOD	O
ALT-17	O
AST-12	O
LD(LDH)-132	O
AlkPhos-144*	O
TotBili-0.4	O
___	O
12:00AM	O
BLOOD	O
Albumin-3.5	O
Calcium-8.5	O
Phos-3.3	O
Mg-2.2	O
Micro:	O
___	O
STOOL	O
CLOSTRIDIUM	O
DIFFICILE	O
TOXIN	O
A	O
&	O
B	O
TEST-FINAL	O
(negative)	O
___	O
STOOL	O
CLOSTRIDIUM	O
DIFFICILE	O
TOXIN	O
A	O
&	O
B	O
TEST-FINAL	O
(negative)	O
___	O
STOOL	O
CLOSTRIDIUM	O
DIFFICILE	O
TOXIN	O
A	O
&	O
B	O
TEST-FINAL	O
(negative)	O
___	O
BLOOD	O
CULTURE	O
Blood	O
Culture,	O
Routine-PENDING	O
INPATIENT	O
___	O
BLOOD	O
CULTURE	O
Blood	O
Culture,	O
Routine-PENDING	O
INPATIENT	O
___	O
URINE	O
URINE	O
CULTURE-FINAL	O
INPATIENT	O
___	O
BLOOD	O
CULTURE	O
Blood	O
Culture,	O
Routine-FINAL	O
INPATIENT	O
___	O
BLOOD	O
CULTURE	O
Blood	O
Culture,	O
Routine-FINAL	O
INPATIENT	O
___	O
BLOOD	O
CULTURE	O
Blood	O
Culture,	O
Routine-FINAL	O
INPATIENT	O
___	O
BLOOD	O
CULTURE	O
Blood	O
Culture,	O
Routine-FINAL	O
INPATIENT	O
___	O
BLOOD	O
CULTURE	O
Blood	O
Culture,	O
Routine-FINAL	O
INPATIENT	O
___	O
URINE	O
Legionella	O
Urinary	O
Antigen	O
-FINAL	O
INPATIENT	O
___	O
BLOOD	O
CULTURE	O
Blood	O
Culture,	O
Routine-FINAL	O
INPATIENT	O
___	O
BLOOD	O
CULTURE	O
Blood	O
Culture,	O
Routine-FINAL	O
INPATIENT	O
___	O
BLOOD	O
CULTURE	O
Blood	O
Culture,	O
Routine-FINAL	O
INPATIENT	O
___	O
BLOOD	O
CULTURE	O
Blood	O
Culture,	O
Routine-FINAL	O
INPATIENT	O
___	O
BLOOD	O
CULTURE	O
Blood	O
Culture,	O
Routine-FINAL	O
INPATIENT	O
___	O
Rapid	O
Respiratory	O
Viral	O
Screen	O
&	O
Culture	O
Respiratory	O
Viral	O
Antigen	O
Screen-FINAL;	O
Respiratory	O
Viral	O
Culture-FINAL	O
INPATIENT	O
___	O
BRONCHOALVEOLAR	O
LAVAGE	O
GRAM	O
STAIN-	O
___	O
11:31	O
am	O
BRONCHOALVEOLAR	O
LAVAGE	O
LINGULA.	O
GRAM	O
STAIN	O
(Final	O
___:	O
1+	O
(<1	O
per	O
1000X	O
FIELD):	O
POLYMORPHONUCLEAR	O
LEUKOCYTES.	O
NO	O
MICROORGANISMS	O
SEEN.	O
RESPIRATORY	O
CULTURE	O
(Final	O
___:	O
10,000-100,000	O
ORGANISMS/ML.	O
Commensal	O
Respiratory	O
Flora.	O
ESCHERICHIA	O
COLI.	O
10,000-100,000	O
ORGANISMS/ML..	O
IDENTIFICATION	O
AND	O
SENSITIVITIES	O
PERFORMED	O
ON	O
CULTURE	O
#	O
___.	O
KLEBSIELLA	O
OXYTOCA.	O
10,000-100,000	O
ORGANISMS/ML..	O
IDENTIFICATION	O
AND	O
SENSITIVITIES	O
PERFORMED	O
ON	O
CULTURE	O
#	O
___	O
___.	O
ACID	O
FAST	O
SMEAR	O
(Final	O
___:	O
NO	O
ACID	O
FAST	O
BACILLI	O
SEEN	O
ON	O
DIRECT	O
SMEAR.	O
NO	O
ACID	O
FAST	O
BACILLI	O
SEEN	O
ON	O
CONCENTRATED	O
SMEAR.	O
ACID	O
FAST	O
CULTURE	O
(Preliminary):	O
NO	O
MYCOBACTERIA	O
ISOLATED.	O
FUNGAL	O
CULTURE	O
(Final	O
___:	O
NO	O
FUNGUS	O
ISOLATED.	O
LEGIONELLA	O
CULTURE	O
(Final	O
___:	O
NO	O
LEGIONELLA	O
ISOLATED.	O
NOCARDIA	O
CULTURE	O
(Preliminary):	O
NO	O
NOCARDIA	O
ISOLATED.	O
Immunoflourescent	O
test	O
for	O
Pneumocystis	O
jirovecii	O
(carinii)	O
(Final	O
___:	O
NEGATIVE	O
for	O
Pneumocystis	O
jirovecii	O
(carinii)..	O
___	O
Rapid	O
Respiratory	O
Viral	O
Screen	O
&	O
Culture	O
Respiratory	O
Viral	O
Antigen	O
Screen-FINAL;	O
Respiratory	O
Viral	O
Culture-FINAL	O
INPATIENT	O
___	O
STOOL	O
CLOSTRIDIUM	O
DIFFICILE	O
TOXIN	O
A	O
&	O
B	O
TEST-FINAL	O
INPATIENT	O
___	O
BLOOD	O
CULTURE	O
Blood	O
Culture,	O
Routine-FINAL	O
INPATIENT	O
___	O
BLOOD	O
CULTURE	O
Blood	O
Culture,	O
Routine-FINAL	O
INPATIENT	O
___	O
BLOOD	O
CULTURE	O
Blood	O
Culture,	O
Routine-FINAL	O
INPATIENT	O
___	O
URINE	O
URINE	O
CULTURE-FINAL	O
INPATIENT	O
___	O
Rapid	O
Respiratory	O
Viral	O
Screen	O
&	O
Culture	O
Respiratory	O
Viral	O
Culture-FINAL;	O
Respiratory	O
Viral	O
Antigen	O
Screen-FINAL	O
INPATIENT	O
___	O
BLOOD	O
CULTURE	O
Blood	O
Culture,	O
Routine-FINAL	O
INPATIENT	O
___	O
BLOOD	O
CULTURE	O
Blood	O
Culture,	O
Routine-FINAL	O
INPATIENT	O
___	O
BLOOD	O
CULTURE	O
Blood	O
Culture,	O
Routine-FINAL	O
INPATIENT	O
___	O
SEROLOGY/BLOOD	O
CRYPTOCOCCAL	O
ANTIGEN-FINAL	O
INPATIENT	O
___	O
URINE	O
NOT	O
PROCESSED	O
INPATIENT	O
___	O
BLOOD	O
CULTURE	O
Blood	O
Culture,	O
Routine-FINAL	O
{PSEUDOMONAS	O
AERUGINOSA};	O
Aerobic	O
Bottle	O
Gram	O
Stain-FINAL	O
___.	O
___	O
BLOOD	O
CULTURE	O
Blood	O
Culture,	O
Routine-FINAL	O
{PSEUDOMONAS	O
AERUGINOSA};	O
Aerobic	O
Bottle	O
Gram	O
Stain-FINAL	O
___.	O
SENSITIVITIES:	O
MIC	O
expressed	O
in	O
MCG/ML	O
_________________________________________________________	O
PSEUDOMONAS	O
AERUGINOSA	O
|	O
AMIKACIN--------------	O
<=2	O
S	O
CEFEPIME--------------	O
8	O
S	O
CEFTAZIDIME-----------	O
4	O
S	O
CIPROFLOXACIN---------	O
1	O
S	O
GENTAMICIN------------	O
<=1	O
S	O
MEROPENEM-------------<=0.25	O
S	O
PIPERACILLIN/TAZO-----	O
16	O
S	O
TOBRAMYCIN------------	O
<=1	O
S	O
___	O
BLOOD	O
CULTURE	O
Blood	O
Culture,	O
Routine-FINAL	O
Imaging:	O
CT	O
chest:	B-Lower_respiratory_tract_infection
IMPRESSION:	O
1.	O
Multiple	O
new	O
bilateral	O
nodular	O
opacities	O
with	O
CT	O
halo	O
sign,	O
the	O
largest	O
in	O
the	O
superior	O
segment	O
of	O
the	O
left	O
lower	O
lobe	O
(16	O
x	O
16	O
mm)	O
are	O
concerning	O
for	O
aspergillosis	O
fungal	O
infection.	B-Lower_respiratory_tract_infection
2.	O
No	O
lymphadenopathy,	O
stable	O
small	O
pericardial	O
effusion.	O
CT	O
abdomen	O
and	O
pelvis:	O
1.	O
No	O
intra-abdominal	O
or	O
pelvic	O
collections.	O
Minimal	O
free	O
fluid	O
within	O
the	O
pelvis.	O
Pericholecystic	O
fluid	O
and	O
periportal	O
edema	O
which	O
may	O
be	O
due	O
to	O
hypoalbuminemia	O
although	O
there	O
is	O
no	O
other	O
evidence	O
of	O
third	O
spacing.	O
2.	O
A	O
4mm	O
ground-glass	O
pulmonary	O
nodule	O
is	O
seen	O
in	O
the	O
right	O
middle	O
lobe,	B-Lower_respiratory_tract_infection
which	O
was	O
not	O
present	O
on	O
the	O
previous	O
CT.	O
This	O
may	O
be	O
infective	B-Lower_respiratory_tract_infection
in	O
nature.Correlation	O
with	O
CT	O
thorax	O
___	O
is	O
recommended.	O
Echo:	O
The	O
left	O
atrium	O
is	O
normal	O
in	O
size.	O
Left	O
ventricular	O
wall	O
thickness,	O
cavity	O
size	O
and	O
regional/global	O
systolic	O
function	O
are	O
normal	O
(LVEF	O
>55%).	O
The	O
estimated	O
cardiac	O
index	O
is	O
high	O
(>4.0L/min/m2).	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal.	O
The	O
ascending	O
aorta	O
is	O
mildly	O
dilated.	O
The	O
aortic	O
valve	O
leaflets	O
(3)	O
appear	O
structurally	O
normal	O
with	O
good	O
leaflet	O
excursion	O
and	O
no	O
aortic	O
stenosis.	O
No	O
masses	O
or	O
vegetations	O
are	O
seen	O
on	O
the	O
aortic	O
valve.	O
Mild	O
(1+)	O
aortic	O
regurgitation	O
is	O
seen.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
structurally	O
normal.	O
There	O
is	O
no	O
mitral	O
valve	O
prolapse.	O
No	O
mass	O
or	O
vegetation	O
is	O
seen	O
on	O
the	O
mitral	O
valve.	O
Trivial	O
mitral	O
regurgitation	O
is	O
seen.	O
There	O
is	O
mild	O
pulmonary	O
artery	O
systolic	O
hypertension.	O
There	O
is	O
a	O
very	O
small	O
pericardial	O
effusion.	O
IMPRESSION:	O
No	O
echocardiographic	O
evidence	O
of	O
endocarditis.	O
Normal	O
global	O
and	O
regional	O
biventricular	O
systolic	O
function.	O
Mild	O
pulmonary	O
hypertension.	O
Mild	O
aortic	O
regurgitation.	O
Brief	O
Hospital	O
Course:	O
___	O
w/	O
AML	O
who	O
presents	O
w/	O
fever,	O
neutropenia,	O
anemia,	O
thrombocytopenia,	O
and	O
failure	O
to	O
thrive.	O
.	O
#	O
Pseudomonas	O
bacteremia,	O
Klebsiella/E.coli	O
Pneumonia:	B-Lower_respiratory_tract_infection
Patient	O
developed	O
neutropenic	O
fever	O
and	O
septic	O
picture	O
soon	O
after	O
admission.	O
She	O
was	O
started	O
on	O
empiric	O
broad	O
spectrum	O
antibiotics	O
(vancomycin	O
and	O
zosyn),	O
with	O
limitations	O
based	O
on	O
her	O
many	O
allergies.	O
Zosyn	O
was	O
run	O
over	O
4	O
hours	O
every	O
8	O
hours	O
to	O
achieve	O
better	O
levels	O
in	O
the	O
blood.	O
She	O
also	O
had	O
findings	O
on	O
CT	O
scan	O
of	O
the	O
chest	B-Lower_respiratory_tract_infection
concerning	O
for	O
fungal	O
infection,	B-Lower_respiratory_tract_infection
so	O
BAL	O
was	O
performed.	O
BAL	O
was	O
negative	O
for	O
fungal	O
infection	O
and	O
instead	O
revealed	O
E.coli	O
and	O
Klebsiella.	O
Since	O
voriconazole	O
dose	O
was	O
determined	O
to	O
be	O
dosed	O
at	O
double	O
the	O
normal	O
dose,	O
it	O
was	O
decreased	O
down	O
to	O
200mg	O
PO	O
Q12.	O
No	O
other	O
fungal	O
therapy	O
was	O
initiated	O
during	O
hospitalization.	O
Ultimately,	O
Ms.	O
___,	O
but	O
never	O
recovered	O
her	O
counts.	O
Though	O
ideally	O
she	O
would	O
complete	O
a	O
course	O
of	O
IV	O
antibiotics	O
given	O
pseudomonal	O
bacteremia,	O
ultimately	O
goals	O
of	O
care	O
discussion	O
led	O
her	O
to	O
decide	O
to	O
switch	O
to	O
PO	O
antibiotics	O
(cefpodoxime)	O
instead	O
and	O
go	O
home	O
rather	O
than	O
go	O
to	O
an	O
extended	O
care	O
facility.	O
#	O
Skin	O
lesions:	O
Derm	O
was	O
consulted	O
for	O
the	O
following	O
lesions:	O
--	O
Skin	O
type	O
II,	O
mild	O
dermatoheliosis	O
--	O
On	O
R	O
upper	O
chest,	O
rough	O
erythematous	O
patch	O
--	O
On	O
L	O
dorsal	O
hand	O
7	O
mm	O
hyperkeratotic	O
cutaneous	O
horn	O
with	O
mildly	O
erythematous	O
base.	O
non-tender	O
--	O
On	O
R	O
extensor	O
arm,	O
5	O
mm	O
shiny,	O
waxy	O
skin	O
colored	O
plaque	O
on	O
distal	O
aspect.	O
there	O
is	O
a	O
5	O
mm	O
hyperkeratotic	O
plaque	O
with	O
erythematous	O
base	O
proximally	O
On	O
the	O
left,	O
felt	O
to	O
be	O
keratoacanthoma	O
(rapidly	O
growing	O
squamous	O
cell	O
cancer	O
variant)	O
vs	O
SCC	O
vs	O
verruca	O
(in	O
setting	O
of	O
immunosuppression)	O
vs	O
less	O
likely	O
seborrheic	O
keratoses	O
or	O
lichenoid	O
keratoses.	O
The	O
hyperkeratotic	O
lesions	O
on	O
the	O
R	O
extensor	O
arm	O
were	O
most	O
likely	O
a	O
hypertrophic	O
actinic	O
keratoses	O
or	O
lichenoid	O
keratoes.	O
Patient	O
will	O
need	O
outpatient	O
follow-up	O
for	O
potential	O
removal	O
if	O
in	O
lines	O
with	O
goals	O
of	O
care.	O
#	O
AML:	O
After	O
discussion	O
with	O
outpatient	O
oncologist,	O
Dr.	O
___	O
opted	O
not	O
to	O
undergo	O
further	O
aggressive	O
chemotherapy	O
and	O
instead	O
to	O
focus	O
on	O
quality	O
of	O
life	O
at	O
her	O
own	O
home.	O
She	O
changed	O
her	O
code	O
status	O
from	O
full	O
code	O
to	O
DNR	O
on	O
this	O
admission	O
as	O
well.	O
Her	O
brother	O
(HCP)	O
and	O
social	O
work	O
were	O
also	O
present	O
for	O
this	O
discussion.	O
Medications	O
on	O
Admission:	O
Brimonidine-Timolol	O
QHS	O
Allopurinol	O
___	O
mg	O
Tablet	O
Clindamycin	O
HCl	O
300	O
mg	O
Capsule	O
QID	O
___	O
BID	O
PRN	O
Lorazepam	O
0.5	O
mg	O
Tablet	O
___	O
tablets	O
QHS	O
and	O
Q8PRN	O
nausea/anxiety	O
Prochlorperazine	O
Maleate	O
5	O
mg	O
Tablet,	O
___	O
Tablet(s)	O
Q6	O
PRN	O
nausea	O
Voriconazole	O
400mg	O
BID	O
Calcium	O
Carbonate-Vitamin	O
D3	O
Discharge	O
Medications:	O
1.	O
Voriconazole	O
200	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
Q12H	O
(every	O
12	O
hours).	O
Disp:*60	O
Tablet(s)*	O
Refills:*1*	O
2.	O
Cefpodoxime	O
100	O
mg	O
Tablet	O
Sig:	O
Two	O
(2)	O
Tablet	O
PO	O
Q12H	O
(every	O
12	O
hours).	O
Disp:*60	O
Tablet(s)*	O
Refills:*2*	O
3.	O
Lorazepam	O
0.5	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
HS	O
(at	O
bedtime)	O
as	O
needed	O
for	O
insomnia.	O
4.	O
Lorazepam	O
0.5	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
Q8H	O
(every	O
8	O
hours)	O
as	O
needed	O
for	O
nausea/anxiety.	O
Disp:*45	O
Tablet(s)*	O
Refills:*0*	O
5.	O
Calcium	O
Carbonate-Vitamin	O
D3	O
600mg	O
(1,000mg)	O
-1,000	O
unit	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
once	O
a	O
day.	O
Disp:*30	O
Tablet(s)*	O
Refills:*2*	O
6.	O
Prochlorperazine	O
Maleate	O
5	O
mg	O
Tablet	O
Sig:	O
___	O
Tablets	O
PO	O
every	O
six	O
(6)	O
hours	O
as	O
needed	O
for	O
nausea.	O
Disp:*30	O
Tablet(s)*	O
Refills:*0*	O
7.	O
___	O
200-25-400-40	O
mg/30	O
mL	O
Mouthwash	O
Sig:	O
One	O
(1)	O
dose	O
Mucous	O
membrane	O
twice	O
a	O
day	O
as	O
needed	O
for	O
indigestion.	O
Disp:*qs	O
1	O
month	O
qs	O
1	O
month*	O
Refills:*0*	O
8.	O
Brimonidine-Timolol	O
0.2-0.5	O
%	O
Drops	O
Sig:	O
One	O
(1)	O
application	O
Ophthalmic	O
at	O
bedtime.	O
Disp:*qs	O
1	O
month	O
qs	O
1	O
month*	O
Refills:*2*	O
9.	O
Nystatin	O
100,000	O
unit/mL	O
Suspension	O
Sig:	O
Five	O
(5)	O
ML	O
PO	O
QID	O
(4	O
times	O
a	O
day).	O
Disp:*qs	O
1	O
month	O
qs	O
1	O
month*	O
Refills:*2*	O
Discharge	O
Disposition:	O
Home	O
With	O
Service	B-Has_carers
Facility:	O
___	O
Discharge	O
Diagnosis:	O
PRIMARY	O
DIAGNOSIS:	O
1.	O
Pseudomonas	O
Bacteremia	O
2.	O
Klebsiella	O
and	O
E.	O
coli	O
Pneumonia	B-Lower_respiratory_tract_infection
3.	O
Febrile	O
Neutropenia	O
4.	O
AML	O
SECONDARY	O
DIAGNOSIS:	O
1.	O
Glaucoma	B-Visual_impairment
Discharge	O
Condition:	O
Mental	B-Delirium
Status:	B-Delirium
Clear	B-Delirium
and	B-Delirium
coherent.	B-Delirium
Level	O
of	O
Consciousness:	O
Alert	O
and	O
interactive.	O
Activity	O
Status:	O
Ambulatory	B-Independently_mobile
-	B-Independently_mobile
Independent.	B-Independently_mobile
Discharge	O
Instructions:	O
You	O
were	O
admitted	O
to	O
the	O
hospital	O
with	O
fevers	O
and	O
had	O
a	O
bloodstream	O
infection	O
and	O
a	O
pneumonia.	B-Lower_respiratory_tract_infection
You	O
were	O
very	O
sick	O
and	O
you	O
were	O
treated	O
with	O
IV	O
antibiotics.	O
Eventually	O
your	O
fevers	O
improved.	O
We	O
had	O
a	O
discussion	O
with	O
you	O
regarding	O
your	O
goals	O
of	O
care,	O
and	O
you	O
decided	O
that	O
you	O
would	O
like	O
to	O
spend	O
the	O
time	O
you	O
have	O
left	O
at	O
home.	O
Therefore,	O
you	O
were	O
discharged	O
from	O
the	O
hospital	O
on	O
an	O
oral	O
antibiotic.	O
You	O
will	O
need	O
to	O
come	O
in	O
for	O
regular	O
laboratory	O
work	O
on	O
___.	O
The	O
following	O
changes	O
have	O
been	O
made	O
to	O
your	O
medications:	O
1.	O
Decrease	O
your	O
voriconazole	O
from	O
400mg	O
twice	O
a	O
day	O
to	O
200mg	O
twice	O
a	O
day	O
2.	O
Start	O
taking	O
cefpodoxime	O
twice	O
a	O
day	O
3.	O
Stop	O
taking	O
clindamycin	O
4.	O
Stop	O
taking	O
allopurinol	O
5.	O
Start	O
using	O
nystatin	O
swish	O
and	O
swallow	O
for	O
your	O
thrush	O
Followup	O
Instructions:	O
___	O

